These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 36803784)

  • 1. P2RX7 promotes osteosarcoma progression and glucose metabolism by enhancing c-Myc stabilization.
    Sheng G; Gao Y; Ding Q; Zhang R; Wang T; Jing S; Zhao H; Ma T; Wu H; Yang Y
    J Transl Med; 2023 Feb; 21(1):132. PubMed ID: 36803784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Her4 promotes cancer metabolic reprogramming via the c-Myc-dependent signaling axis.
    Han J; Zhang Y; Xu J; Zhang T; Wang H; Wang Z; Jiang Y; Zhou L; Yang M; Hua Y; Cai Z
    Cancer Lett; 2021 Jan; 496():57-71. PubMed ID: 33038488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma.
    Shen Y; Zhao S; Wang S; Pan X; Zhang Y; Xu J; Jiang Y; Li H; Zhang Q; Gao J; Yang Q; Zhou Y; Jiang S; Yang H; Zhang Z; Zhang R; Li J; Zhou D
    EBioMedicine; 2019 Feb; 40():210-223. PubMed ID: 30587459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CircECE1 activates energy metabolism in osteosarcoma by stabilizing c-Myc.
    Shen S; Yao T; Xu Y; Zhang D; Fan S; Ma J
    Mol Cancer; 2020 Oct; 19(1):151. PubMed ID: 33106166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional heterogeneity of MCT1 and MCT4 in metabolic reprogramming affects osteosarcoma growth and metastasis.
    Sheng G; Gao Y; Wu H; Liu Y; Yang Y
    J Orthop Surg Res; 2023 Feb; 18(1):131. PubMed ID: 36814318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly-expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β-catenin and mTOR/HIF1α/VEGF signaling.
    Zhang Y; Cheng H; Li W; Wu H; Yang Y
    Int J Cancer; 2019 Aug; 145(4):1068-1082. PubMed ID: 30761524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR‑193b exhibits mutual interaction with MYC, and suppresses growth and metastasis of osteosarcoma.
    Gao J; Ma S; Yang F; Chen X; Wang W; Zhang J; Li Y; Wang T; Shan L
    Oncol Rep; 2020 Jul; 44(1):139-155. PubMed ID: 32377743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Construction of antisense c-myc recombinant adenovirus and its anti-tumor effects on osteosarcoma cell lines MG-63 and U2OS].
    Xie XK; Yang DS; Ye ZM; Tao HM
    Ai Zheng; 2005 Mar; 24(3):292-7. PubMed ID: 15757529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDGFRβ modulates aerobic glycolysis in osteosarcoma HOS cells via the PI3K/AKT/mTOR/c-Myc pathway.
    Tang HY; Guo JQ; Sang BT; Cheng JN; Wu XM
    Biochem Cell Biol; 2022 Feb; 100(1):75-84. PubMed ID: 34678088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential value of lncRNA-BC050642 in osteosarcoma origination and outcomes.
    Yang Y; Fei M; Zhou X; Li Y; Jin D
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1859-1866. PubMed ID: 31397185
    [No Abstract]   [Full Text] [Related]  

  • 11. The SIRT2/cMYC Pathway Inhibits Peroxidation-Related Apoptosis In Cholangiocarcinoma Through Metabolic Reprogramming.
    Xu L; Wang L; Zhou L; Dorfman RG; Pan Y; Tang D; Wang Y; Yin Y; Jiang C; Zou X; Wu J; Zhang M
    Neoplasia; 2019 May; 21(5):429-441. PubMed ID: 30933885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KPNA2 promotes metabolic reprogramming in glioblastomas by regulation of c-myc.
    Li J; Liu Q; Liu Z; Xia Q; Zhang Z; Zhang R; Gao T; Gu G; Wang Y; Wang D; Chen X; Yang Y; He D; Xin T
    J Exp Clin Cancer Res; 2018 Aug; 37(1):194. PubMed ID: 30115078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CircMYO10 promotes osteosarcoma progression by regulating miR-370-3p/RUVBL1 axis to enhance the transcriptional activity of β-catenin/LEF1 complex via effects on chromatin remodeling.
    Chen J; Liu G; Wu Y; Ma J; Wu H; Xie Z; Chen S; Yang Y; Wang S; Shen P; Fang Y; Fan S; Shen S; Fang X
    Mol Cancer; 2019 Oct; 18(1):150. PubMed ID: 31665067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosensitizing effects of c‑myc gene knockdown‑induced G2/M phase arrest by intrinsic stimuli via the mitochondrial signaling pathway.
    Fan Y; Jia X; Xie T; Zhu L; He F
    Oncol Rep; 2020 Dec; 44(6):2669-2677. PubMed ID: 33125136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myc upregulates Ggct, γ-glutamylcyclotransferase to promote development of p53-deficient osteosarcoma.
    Ueno T; Otani S; Date Y; Katsuma Y; Nagayoshi Y; Ito T; Ii H; Kageyama S; Nakata S; Ito K
    Cancer Sci; 2024 Sep; 115(9):2961-2971. PubMed ID: 38924236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baicalein suppresses the viability of MG-63 osteosarcoma cells through inhibiting c-MYC expression via Wnt signaling pathway.
    He N; Zhang Z
    Mol Cell Biochem; 2015 Jul; 405(1-2):187-96. PubMed ID: 25893737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A newly synthesized oleanolic acid derivative inhibits the growth of osteosarcoma cells in vitro and in vivo by decreasing c-MYC-dependent glycolysis.
    Gao F; Zuo Q; Jiang T; Song H; Zhou J
    J Cell Biochem; 2019 Jun; 120(6):9264-9276. PubMed ID: 30552712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-33b suppresses migration and invasion by targeting c-Myc in osteosarcoma cells.
    Xu N; Li Z; Yu Z; Yan F; Liu Y; Lu X; Yang W
    PLoS One; 2014; 9(12):e115300. PubMed ID: 25546234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-MYC-directed NRF2 drives malignant progression of head and neck cancer via glucose-6-phosphate dehydrogenase and transketolase activation.
    Tang YC; Hsiao JR; Jiang SS; Chang JY; Chu PY; Liu KJ; Fang HL; Lin LM; Chen HH; Huang YW; Chen YT; Tsai FY; Lin SF; Chuang YJ; Kuo CC
    Theranostics; 2021; 11(11):5232-5247. PubMed ID: 33859744
    [No Abstract]   [Full Text] [Related]  

  • 20. C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression.
    Gamberi G; Benassi MS; Bohling T; Ragazzini P; Molendini L; Sollazzo MR; Pompetti F; Merli M; Magagnoli G; Balladelli A; Picci P
    Oncology; 1998; 55(6):556-63. PubMed ID: 9778623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.